| Reference |
Sentence |
Publish Date |
Extraction Date |
Species |
| Saki Hattori, Akira Suda, Ikuko Kishida, Masatoshi Miyauchi, Yohko Shiraishi, Nobuhiko Noguchi, Taku Furuno, Takeshi Asami, Mami Fujibayashi, Natsuki Tsujita, Chie Ishii, Norio Ishii, Takashi Saeki, Tadashi Fukushima, Toshio Moritani, Yusuke Saigusa, Akitoyo Hishimot. Differences in autonomic nervous system activity between long-acting injectable aripiprazole and oral aripiprazole in schizophrenia. BMC psychiatry vol 23 issue 1 2023 36869320 |
differences in autonomic nervous system activity between long-acting injectable aripiprazole and oral aripiprazole in schizophrenia. |
2023-03-03 |
2023-03-06 |
Not clear |
| Saki Hattori, Akira Suda, Ikuko Kishida, Masatoshi Miyauchi, Yohko Shiraishi, Nobuhiko Noguchi, Taku Furuno, Takeshi Asami, Mami Fujibayashi, Natsuki Tsujita, Chie Ishii, Norio Ishii, Takashi Saeki, Tadashi Fukushima, Toshio Moritani, Yusuke Saigusa, Akitoyo Hishimot. Differences in autonomic nervous system activity between long-acting injectable aripiprazole and oral aripiprazole in schizophrenia. BMC psychiatry vol 23 issue 1 2023 36869320 |
among them, oral aripiprazole has been linked to dysfunction of the ans in schizophrenia. |
2023-03-03 |
2023-03-06 |
Not clear |
| Saki Hattori, Akira Suda, Ikuko Kishida, Masatoshi Miyauchi, Yohko Shiraishi, Nobuhiko Noguchi, Taku Furuno, Takeshi Asami, Mami Fujibayashi, Natsuki Tsujita, Chie Ishii, Norio Ishii, Takashi Saeki, Tadashi Fukushima, Toshio Moritani, Yusuke Saigusa, Akitoyo Hishimot. Differences in autonomic nervous system activity between long-acting injectable aripiprazole and oral aripiprazole in schizophrenia. BMC psychiatry vol 23 issue 1 2023 36869320 |
in this study, we compared ans activity between oral aripiprazole and aripiprazole once-monthly (aom) in schizophrenia. |
2023-03-03 |
2023-03-06 |
Not clear |
| Heidi C Waters, Robert Stellhorn, Maelys Touya, Heather Fitzgerald, Sandipan Bhattacharjee, Leslie Citrom. The effects of early initiation of aripiprazole once-monthly on healthcare resource utilization and healthcare costs in individuals with schizophrenia: real-world evidence from US claims data. Journal of medical economics vol issue 2023 36780296 |
the effects of early initiation of aripiprazole once-monthly on healthcare resource utilization and healthcare costs in individuals with schizophrenia: real-world evidence from us claims data. |
2023-02-13 |
2023-03-06 |
Not clear |
| Heidi C Waters, Robert Stellhorn, Maelys Touya, Heather Fitzgerald, Sandipan Bhattacharjee, Leslie Citrom. The effects of early initiation of aripiprazole once-monthly on healthcare resource utilization and healthcare costs in individuals with schizophrenia: real-world evidence from US claims data. Journal of medical economics vol issue 2023 36780296 |
to evaluate the impact of timing of aripiprazole once-monthly (aom) initiation on healthcare resource utilization (hcru), risk of hospitalization, and healthcare costs in patients with schizophrenia. |
2023-02-13 |
2023-03-06 |
Not clear |
| Chittaranjan Andrad. Prolactin-Raising and Prolactin-Sparing Antipsychotic Drugs and the Risk of Fracture and Fragility Fracture in Patients With Schizophrenia, Dementia, and Other Disorders. The Journal of clinical psychiatry vol 84 issue 1 2023 36724110 |
an observational study that controlled for confounding by indication and illness severity found that fragility fractures in patients with schizophrenia were associated with higher daily doses, higher cumulative doses, longer duration of treatment, and prolactin-raising rather than prolactin-sparing antipsychotics; in patients receiving prolactin-raising antipsychotics, the concurrent use of aripiprazole appeared protective. |
2023-02-01 |
2023-03-06 |
Not clear |
| Heidi C Waters, Maelys Touya, Soon Nan Wee, Michelle Ng, Simran Thadani, Subina Surendran, Miguel Renter\\xc3\\xada, A John Rush, Rashmi Patel, Joydeep Sarkar, Heather M Fitzgerald, Xue Ha. Psychiatric healthcare resource utilization following initiation of aripiprazole once-monthly: a retrospective real-world study. Current medical research and opinion vol 39 issue 2 2023 36380678 |
this observational retrospective real-world study examined changes in healthcare resource utilization (hcru) pre- and post-initiation of aripiprazole once-monthly (aom 400) in patients with schizophrenia or bipolar i disorder. |
2023-01-30 |
2023-01-31 |
Not clear |
| Yusuke Okada, Ken Inada, Manabu Akazaw. Comparative effectiveness of long-acting injectable antipsychotics in patients with schizophrenia in Japan. Schizophrenia research vol 252 issue 2023 36706475 |
to compare the effectiveness of different long-acting injectable antipsychotics (lais) (aripiprazole, paliperidone, risperidone, and fluphenazine/haloperidol) in patients with schizophrenia in japan. |
2023-01-27 |
2023-01-31 |
Not clear |
| Sung-Wan Kim, Bong-Ju Lee, Eun-Jin Cheon, Seung-Hee Won, Anna Jo, Jae-Min Kim, Young-Chul Chun. Effectiveness of Switching to Long-acting Injectable Aripiprazole in Patients with Recent-onset and Chronic Schizophrenia. Clinical psychopharmacology and neuroscience : the official scientific journal of the Korean College of Neuropsychopharmacology vol 21 issue 1 2023 36700312 |
effectiveness of switching to long-acting injectable aripiprazole in patients with recent-onset and chronic schizophrenia. |
2023-01-26 |
2023-01-31 |
Not clear |
| Sung-Wan Kim, Bong-Ju Lee, Eun-Jin Cheon, Seung-Hee Won, Anna Jo, Jae-Min Kim, Young-Chul Chun. Effectiveness of Switching to Long-acting Injectable Aripiprazole in Patients with Recent-onset and Chronic Schizophrenia. Clinical psychopharmacology and neuroscience : the official scientific journal of the Korean College of Neuropsychopharmacology vol 21 issue 1 2023 36700312 |
this study investigated the effectiveness of switching to once-monthly long-acting injectable (lai) aripiprazole from other second-generation antipsychotics including lai paliperidone palmitate in both recent-onset and chronic schizophrenia patients. |
2023-01-26 |
2023-01-31 |
Not clear |
| Ahmed M Abdelfattah, Sally A Abuelezz, Nevien Hendawy, Eman A Negm, Salwa Abd El Khalek Nawishy, Ahmed Mohamed Mohamed Khali. Sonic hedgehog pathway as a new target of atypical antipsychotics: Revisiting of amisulpride and aripiprazole effects in a rat model of schizophrenia. Life sciences vol issue 2023 36649751 |
sonic hedgehog pathway as a new target of atypical antipsychotics: revisiting of amisulpride and aripiprazole effects in a rat model of schizophrenia. |
2023-01-17 |
2023-01-30 |
rat |
| Ahmed M Abdelfattah, Sally A Abuelezz, Nevien Hendawy, Eman A Negm, Salwa Abd El Khalek Nawishy, Ahmed Mohamed Mohamed Khali. Sonic hedgehog pathway as a new target of atypical antipsychotics: Revisiting of amisulpride and aripiprazole effects in a rat model of schizophrenia. Life sciences vol issue 2023 36649751 |
in this study, effects of the anti-psychotics amisulpride and/or aripiprazole on the shh-pathway and its relation to cognitive functions and neurogenesis in a rat model of schizophrenia were tested. |
2023-01-17 |
2023-01-30 |
rat |
| Alessandro Cuomo, Eugenio Aguglia, Stefano Biagini, Alessandro Carano, Massimo Clerici, Armando D'Agostino, Sergio De Filippis, Serafino De Giorgi, Arianna Goracci, Claudia Libri, Francesco Lombardi, Matteo Lupi, Giuseppe Maina, Giovanni Martinotti, Pietro Nigro, Mauro Pettorruso, Valerio Ricci, Eros Rossi, Felicia Russo, Andrea Fagiolin. Two-Injection Start Regimen of Long-Acting Aripiprazole in 133 Patients With Schizophrenia. Journal of clinical psychopharmacology vol 43 issue 1 2022 36584247 |
two-injection start regimen of long-acting aripiprazole in 133 patients with schizophrenia. |
2022-12-30 |
2023-01-30 |
Not clear |
| I Yu Dorozheno. [Modern possibilities of anti-relapse therapy of schizophrenia (experience with the use of aripiprazole)]. Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova vol 122 issue 12 2022 36537633 |
[modern possibilities of anti-relapse therapy of schizophrenia (experience with the use of aripiprazole)]. |
2022-12-20 |
2023-01-30 |
Not clear |
| I Yu Dorozheno. [Modern possibilities of anti-relapse therapy of schizophrenia (experience with the use of aripiprazole)]. Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova vol 122 issue 12 2022 36537633 |
according to numerous studies, aripiprazole, due to its unique pharmacological profile and combination of clinical factors, is the drug of first choice for anti-relapse supportive therapy of schizophrenia. |
2022-12-20 |
2023-01-30 |
Not clear |
| Zhizhong Xu, Chunyan Wen, Yinghua Huang, Qianfa Yuan, Xianhua Zhang, Duoduo Lin, Liangsheng Liu, Wenqiang Wan. Effects of Glycogen Synthase Kinase-3 Beta Gene Polymorphisms on the Plasma Concentration of Aripiprazole in Chinese Patients with Schizophrenia: A Preliminary Study. Journal of molecular neuroscience : MN vol issue 2022 36539584 |
effects of glycogen synthase kinase-3 beta gene polymorphisms on the plasma concentration of aripiprazole in chinese patients with schizophrenia: a preliminary study. |
2022-12-20 |
2023-01-30 |
Not clear |
| Zhizhong Xu, Chunyan Wen, Yinghua Huang, Qianfa Yuan, Xianhua Zhang, Duoduo Lin, Liangsheng Liu, Wenqiang Wan. Effects of Glycogen Synthase Kinase-3 Beta Gene Polymorphisms on the Plasma Concentration of Aripiprazole in Chinese Patients with Schizophrenia: A Preliminary Study. Journal of molecular neuroscience : MN vol issue 2022 36539584 |
this study explored the differences in glycogen synthase kinase-3 beta (gsk3\xce\xb2) gene polymorphisms between patients with schizophrenia and healthy controls and investigated the association between gene polymorphisms and plasma concentration of aripiprazole. |
2022-12-20 |
2023-01-30 |
Not clear |
| Howard C Margolese, Matthieu Boucher, Francois Therrien, Guerline Clerziu. Treatment with aripiprazole once-monthly injectable formulation is effective in improving symptoms and global functioning in schizophrenia with and without comorbid substance use - a post hoc analysis of the ReLiAM study. BMC psychiatry vol 22 issue 1 2022 36482352 |
treatment with aripiprazole once-monthly injectable formulation is effective in improving symptoms and global functioning in schizophrenia with and without comorbid substance use - a post hoc analysis of the reliam study. |
2022-12-09 |
2023-01-30 |
Not clear |
| Howard C Margolese, Matthieu Boucher, Francois Therrien, Guerline Clerziu. Treatment with aripiprazole once-monthly injectable formulation is effective in improving symptoms and global functioning in schizophrenia with and without comorbid substance use - a post hoc analysis of the ReLiAM study. BMC psychiatry vol 22 issue 1 2022 36482352 |
reliam, real-life assessment of abilify maintena, was the first reported long-term prospective non-interventional study for patients with schizophrenia treated with aripiprazole once-monthly injectable formulation (aom) under real-life conditions. |
2022-12-09 |
2023-01-30 |
Not clear |
| Karl Josef F\\xc3\\xb6hr, Michael Rapp, Michael Fauler, Thomas Zimmer, Bettina Jungwirth, David Alexander Christian Messere. Block of Voltage-Gated Sodium Channels by Aripiprazole in a State-Dependent Manner. International journal of molecular sciences vol 23 issue 21 2022 36361681 |
aripiprazole is an atypical antipsychotic drug, which is prescribed for many psychiatric diseases such as schizophrenia and mania in bipolar disorder. |
2022-11-11 |
2023-01-30 |
Not clear |